🟢 Ind-Swift Laboratories is trading 5.61% up today after strong Q1 FY27 results

Ind-Swift Laboratories is trading 5.61% up now at INR 330.59, as investors continue responding to strong Q1 FY27 results and the August 17 earnings-call update.

• Operating EBITDA rose 2.85x year over year, while adjusted PAT increased 2.04x.
• Viatris, Manx, and Arrotex CDMO partnerships are expected to add INR 200–220 crore in FY27 revenue.
• The rally extends gains of 20.00% on August 11 and 5.38% on August 12; no separate August 18 announcement or broader-market catalyst was identified.